$MOH
MOLINA HEALTHCARE, INC.

2020 Q2 Form 10-Q Financial Statement

#000117992920000111 Filed on July 31, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $4.618B $4.193B
YoY Change 10.14% -14.13%
Cost Of Revenue $3.598B $3.466B
YoY Change 3.81% -12.65%
Gross Profit $1.020B $583.0M
YoY Change 74.96% -13.37%
Gross Profit Margin 22.09% 13.9%
Selling, General & Admin $573.0M $438.0M
YoY Change 30.82% -18.89%
% of Gross Profit 56.18% 75.13%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $21.00M $22.00M
YoY Change -4.55% -38.89%
% of Gross Profit 2.06% 3.77%
Operating Expenses $594.0M $460.0M
YoY Change 29.13% -18.58%
Operating Profit $424.0M $265.0M
YoY Change 60.0% -22.51%
Interest Expense $24.00M $22.00M
YoY Change 9.09% -31.25%
% of Operating Profit 5.66% 8.3%
Other Income/Expense, Net -$29.00M -$8.000M
YoY Change 262.5% -78.38%
Pretax Income $395.0M $257.0M
YoY Change 53.7% -15.74%
Income Tax $119.0M $61.00M
% Of Pretax Income 30.13% 23.74%
Net Earnings $276.0M $196.0M
YoY Change 40.82% -2.97%
Net Earnings / Revenue 5.98% 4.67%
Basic Earnings Per Share $4.72 $3.15
Diluted Earnings Per Share $4.65 $3.06
COMMON SHARES
Basic Shares Outstanding 58.60M shares 62.10M shares
Diluted Shares Outstanding 59.40M shares 64.00M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.209B $4.323B
YoY Change 20.5% -22.36%
Cash & Equivalents $3.303B $2.253B
Short-Term Investments $1.906B $2.070B
Other Short-Term Assets $273.0M $301.0M
YoY Change -9.3% -77.04%
Inventory
Prepaid Expenses
Receivables $1.580B $1.239B
Other Receivables $0.00 $0.00
Total Short-Term Assets $7.062B $5.863B
YoY Change 20.45% -26.96%
LONG-TERM ASSETS
Property, Plant & Equipment $399.0M $373.0M
YoY Change 6.97% 35.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $99.00M $106.0M
YoY Change -6.6% 278.57%
Total Long-Term Assets $814.0M $827.0M
YoY Change -1.57% 12.36%
TOTAL ASSETS
Total Short-Term Assets $7.062B $5.863B
Total Long-Term Assets $814.0M $827.0M
Total Assets $7.876B $6.690B
YoY Change 17.73% -23.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $876.0M $337.0M
YoY Change 159.94% -55.31%
Accrued Expenses $29.00M
YoY Change
Deferred Revenue $54.00M $30.00M
YoY Change 80.0% -84.46%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $72.00M
YoY Change -85.12%
Total Short-Term Liabilities $3.755B $3.388B
YoY Change 10.83% -41.79%
LONG-TERM LIABILITIES
Long-Term Debt $1.812B $1.241B
YoY Change 46.01% 21.79%
Other Long-Term Liabilities $84.00M $93.00M
YoY Change -9.68% 36.76%
Total Long-Term Liabilities $1.896B $1.334B
YoY Change 42.13% 22.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.755B $3.388B
Total Long-Term Liabilities $1.896B $1.334B
Total Liabilities $5.880B $4.954B
YoY Change 18.69% -30.27%
SHAREHOLDERS EQUITY
Retained Earnings $1.798B $1.491B
YoY Change 20.59% 142.83%
Common Stock $166.0M $240.0M
YoY Change -30.83% -77.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.996B $1.736B
YoY Change
Total Liabilities & Shareholders Equity $7.876B $6.690B
YoY Change 17.73% -23.66%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income $276.0M $196.0M
YoY Change 40.82% -2.97%
Depreciation, Depletion And Amortization $21.00M $22.00M
YoY Change -4.55% -38.89%
Cash From Operating Activities $606.0M -$93.00M
YoY Change -751.61% 16.25%
INVESTING ACTIVITIES
Capital Expenditures -$24.00M -$14.00M
YoY Change 71.43% 40.0%
Acquisitions
YoY Change
Other Investing Activities $165.0M -$550.0M
YoY Change -130.0% -309.13%
Cash From Investing Activities $141.0M -$564.0M
YoY Change -125.0% -322.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 196.0M -314.0M
YoY Change -162.42% -36.95%
NET CHANGE
Cash From Operating Activities 606.0M -93.00M
Cash From Investing Activities 141.0M -564.0M
Cash From Financing Activities 196.0M -314.0M
Net Change In Cash 943.0M -971.0M
YoY Change -197.12% 198.77%
FREE CASH FLOW
Cash From Operating Activities $606.0M -$93.00M
Capital Expenditures -$24.00M -$14.00M
Free Cash Flow $630.0M -$79.00M
YoY Change -897.47% 12.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
dei Trading Symbol
TradingSymbol
MOH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59300000 shares
CY2020Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
4372000000 USD
CY2019Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
4049000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
8676000000 USD
us-gaap Premiums Earned Net
PremiumsEarnedNet
8001000000 USD
CY2020Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
157000000 USD
CY2019Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
110000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
307000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
248000000 USD
CY2020Q2 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
71000000 USD
CY2019Q2 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
137000000 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
CY2020Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
18000000 USD
CY2019Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
34000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
47000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
63000000 USD
CY2020Q2 us-gaap Revenues
Revenues
4618000000 USD
CY2019Q2 us-gaap Revenues
Revenues
4193000000 USD
us-gaap Revenues
Revenues
9167000000 USD
us-gaap Revenues
Revenues
8312000000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3598000000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3466000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7314000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6837000000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
345000000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
328000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
662000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
630000000 USD
CY2020Q2 moh Premium Tax Expenses
PremiumTaxExpenses
157000000 USD
CY2019Q2 moh Premium Tax Expenses
PremiumTaxExpenses
110000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
307000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
248000000 USD
CY2020Q2 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
71000000 USD
CY2019Q2 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
139000000 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
3928000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
8469000000 USD
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
21000000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
41000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
47000000 USD
CY2020Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2000000 USD
CY2019Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2000000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
6000000 USD
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
5000000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
4194000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7767000000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
424000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
265000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
698000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
545000000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
24000000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
22000000 USD
us-gaap Interest Expense
InterestExpense
45000000 USD
us-gaap Interest Expense
InterestExpense
45000000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29000000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
395000000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
257000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
648000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
517000000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
119000000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
61000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
194000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
us-gaap Net Income Loss
NetIncomeLoss
454000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.72
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.34
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.65
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.04
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
us-gaap Net Income Loss
NetIncomeLoss
454000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
62000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
10000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
37000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
17000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
15000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
2000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
9000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
4000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
28000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
323000000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
204000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
482000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
407000000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3303000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2452000000 USD
CY2020Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1906000000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1946000000 USD
CY2020Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1580000000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1406000000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
273000000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
163000000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
7062000000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5967000000 USD
CY2020Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
399000000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
385000000 USD
CY2020Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
164000000 USD
CY2019Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
172000000 USD
CY2020Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
87000000 USD
CY2019Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
79000000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
65000000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
79000000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
99000000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000000 USD
CY2020Q2 us-gaap Assets
Assets
7876000000 USD
CY2019Q4 us-gaap Assets
Assets
6787000000 USD
CY2020Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1960000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2020Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
865000000 USD
CY2019Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
664000000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
876000000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
502000000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
54000000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
249000000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3755000000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3269000000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1812000000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1237000000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
229000000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
231000000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
84000000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
90000000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
5880000000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
4827000000 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59000000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62000000 shares
CY2020Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
166000000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
175000000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
32000000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1798000000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1781000000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1996000000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1960000000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7876000000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6787000000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1960000000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
178000000 USD
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
446000000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-30000000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-19000000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4000000 USD
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
47000000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
26000000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1996000000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
198000000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-103000000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1835000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-321000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1736000000 USD
us-gaap Net Income Loss
NetIncomeLoss
454000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
47000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-6000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-19000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
28000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
17000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-1000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
7000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
174000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-91000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
157000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
106000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
-194000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
201000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
17000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
251000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-61000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-195000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-181000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
184000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-3000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
749000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
156000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
670000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1162000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
750000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
791000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
45000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-393000000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
789000000 USD
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
600000000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
453000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
380000000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
220000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
30000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
424000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
27000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
473000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
27000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
473000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12000000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
185000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-3000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
27000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-362000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
858000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-599000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2508000000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2926000000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3366000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2327000000 USD
us-gaap Stock Issued1
StockIssued1
8000000 USD
us-gaap Stock Issued1
StockIssued1
7000000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The determination of medical claims and benefits payable of our Health Plans segment;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Settlements under risk or savings sharing programs;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The determination of reserves for the outcome of litigation;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The determination of valuation allowances for deferred tax assets; and</span></div>•The determination of unrecognized tax benefits.
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3303000000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2253000000 USD
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
63000000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
74000000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3366000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2327000000 USD
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
moh Investments Average Maturity Period
InvestmentsAverageMaturityPeriod
P10Y
CY2020Q2 us-gaap Interest Receivable
InterestReceivable
10000000 USD
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
12000000 USD
CY2020Q2 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
85000000 USD
CY2019Q4 moh Medical Premiums Liability Medical Care Costs Threshold
MedicalPremiumsLiabilityMedicalCareCostsThreshold
92000000 USD
CY2020Q2 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
105000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Medicaid Other
AmountsDueToGovernmentAgenciesMedicaidOther
95000000 USD
CY2020Q2 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
38000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Risk Adjustment And Part D Risk Sharing
AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
14000000 USD
CY2020Q2 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
16000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Medicare Medical Loss Ratio And Profit Sharing Threshold
AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
36000000 USD
CY2020Q2 moh Other Medicare Program
OtherMedicareProgram
24000000 USD
CY2019Q4 moh Other Medicare Program
OtherMedicareProgram
21000000 USD
CY2020Q2 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
529000000 USD
CY2019Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
368000000 USD
CY2020Q2 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
41000000 USD
CY2019Q4 moh Amounts Due To Government Agencies Marketplace Medical Loss Ratio Threshold
AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
15000000 USD
CY2020Q2 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
27000000 USD
CY2019Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
23000000 USD
CY2020Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
865000000 USD
CY2019Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
664000000 USD
CY2020Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
-529000000 USD
CY2020Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
72000000 USD
CY2020Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
457000000 USD
CY2020Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable Payable Current Year
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear
160000000 USD
CY2020Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable Prior Years
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
297000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
368000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
63000000 USD
CY2019Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
305000000 USD
CY2020Q2 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
65000000 USD
CY2019Q2 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
46000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
126000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
91000000 USD
CY2020Q2 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
58000000 USD
CY2019Q2 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
37000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
102000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
63000000 USD
CY2020Q2 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
7000000 USD
CY2019Q2 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
10000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
19000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
30000000 USD
CY2020Q2 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
65000000 USD
CY2019Q2 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
47000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
121000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
93000000 USD
CY2020Q2 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.015
CY2019Q2 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.014
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
CY2020Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1580000000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1406000000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate.
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
CY2020Q2 moh Health Care Insurance Fee Liability
HealthCareInsuranceFeeLiability
277000000 USD
CY2020Q1 moh Health Care Insurance Fee Liability
HealthCareInsuranceFeeLiability
271000000 USD
moh Increase Decrease In Health Insurance Fee Liability
IncreaseDecreaseInHealthInsuranceFeeLiability
6000000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
276000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
us-gaap Net Income Loss
NetIncomeLoss
454000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
CY2020Q1 us-gaap Shares Outstanding
SharesOutstanding
58600000 shares
CY2019Q1 us-gaap Shares Outstanding
SharesOutstanding
62100000 shares
CY2019Q4 us-gaap Shares Outstanding
SharesOutstanding
61900000 shares
CY2018Q4 us-gaap Shares Outstanding
SharesOutstanding
62100000 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
2500000 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58600000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62100000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59400000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62100000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1300000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2400000 shares
CY2020Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
800000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
800000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59400000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64000000.0 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60200000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65100000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.72
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.34
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.65
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.04
CY2019Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1767000000 USD
CY2020Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1906000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1946000000 USD
CY2019Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1975000000 USD
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
29000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1864000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
47000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1906000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1941000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000000 USD
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
6000000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1946000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
263000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
265000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
979000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1009000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
172000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
176000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
450000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
456000000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1864000000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
1906000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
1000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
116000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
5000000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
63 Security
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 Security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
365000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
239 Security
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0 Security
CY2020Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
87000000 USD
CY2020Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
83000000 USD
CY2020Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
4000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:69.994%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.636%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.637%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30,<br/>2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In millions)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fee-for-service claims incurred but not paid (“IBNP”)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,432 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,406 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pharmacy payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">126 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capitation payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">267 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,960 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,854 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div>
CY2020Q2 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1432000000 USD
CY2019Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1406000000 USD
CY2020Q2 moh Pharmacy Claims Payable
PharmacyClaimsPayable
132000000 USD
CY2019Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
126000000 USD
CY2020Q2 moh Capitation Claims Payable
CapitationClaimsPayable
74000000 USD
CY2019Q4 moh Capitation Claims Payable
CapitationClaimsPayable
55000000 USD
CY2020Q2 moh Other Claims Payable
OtherClaimsPayable
322000000 USD
CY2019Q4 moh Other Claims Payable
OtherClaimsPayable
267000000 USD
CY2020Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1960000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2020Q2 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
86000000 USD
CY2019Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
132000000 USD
CY2019Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1854000000 USD
CY2018Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1961000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
7372000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
7069000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
58000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
232000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
7314000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
6837000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
-34000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
4000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
5688000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
5585000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1486000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1450000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
7174000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
7035000000 USD
CY2020Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1960000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
58000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
232000000 USD
CY2020Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18000000 USD
CY2020Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
18000000 USD
CY2019Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
7000000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1812000000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1237000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5000000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000000 USD
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
16000000 USD
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
10000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
28000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
85000000 USD
moh Unrecognized Compensation Forfeited Rate
UnrecognizedCompensationForfeitedRate
0.113
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
771758 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
102.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
503721 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
123.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
168295 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
93.34
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
46169 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
103.65
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1061015 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
113.31
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
62000000 USD
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
49000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
21000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
20000000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2020Q2 us-gaap Revenues
Revenues
4618000000 USD
CY2019Q2 us-gaap Revenues
Revenues
4193000000 USD
us-gaap Revenues
Revenues
9167000000 USD
us-gaap Revenues
Revenues
8312000000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
424000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
265000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
698000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
545000000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-29000000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
395000000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
257000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
648000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
517000000 USD

Files In Submission

Name View Source Status
0001179929-20-000111-index-headers.html Edgar Link pending
0001179929-20-000111-index.html Edgar Link pending
0001179929-20-000111.txt Edgar Link pending
0001179929-20-000111-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-20200630.htm Edgar Link pending
moh-20200630.xsd Edgar Link pending
moh-20200630_cal.xml Edgar Link unprocessable
moh-20200630_def.xml Edgar Link unprocessable
moh-20200630_g1.jpg Edgar Link pending
moh-20200630_htm.xml Edgar Link completed
moh-20200630_lab.xml Edgar Link unprocessable
moh-20200630_pre.xml Edgar Link unprocessable
moh2q20ex311.htm Edgar Link pending
moh2q20ex312.htm Edgar Link pending
moh2q20ex321.htm Edgar Link pending
moh2q20ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending